-
Argentine scientists lay first traps in hantavirus hunt
-
Star of Rome's 'sexy priest' calendar admits: 'I was never a priest'
-
Harry Styles fans to splash over £1 bn on London concerts: Barclays
-
Bolivia protest sees violent clashes, looting in La Paz
-
Trump says held off on new Iran attack, upbeat for agreement
-
Los Angeles World Cup workers vow strike over ICE guarantees
-
Three killed in San Diego mosque shooting, two attackers dead
-
US to screen for Ebola at airports, one American in DR Congo infected
-
Aussie Scott officially set for 100th straight major at US Open
-
Pep Guardiola to leave Man City at end of the season - reports
-
Neymar back in Brazil squad for fourth World Cup
-
Arsenal on the brink of Premier League title after nervy Burnley win
-
Oil rises, global stocks mixed as markets track Iran developments
-
World Cup winner Pavard confirms Marseille exit
-
Trump says holding off on new Iran attack
-
Cuba warns of 'bloodbath' if US attacks; Washington adds sanctions
-
Trump says delaying Iran attack at request of Gulf leaders
-
Cuba warns of 'bloodbath' if US attacks and Washington issues sanctions
-
After mayor's murder, Mexico battles to bring peace
-
Trump admin creates $1.7 bln fund to compensate allies prosecuted under Biden
-
Pelicans name Mosley as coach, two weeks after Magic firing
-
Hyderabad qualify for IPL play-offs along with Gujarat
-
'Girl in the River Main' identified 25 years on, father arrested
-
Musk loses blockbuster OpenAI suit as jury says too late
-
SNC Scandic Coin and Biconomy: Regulated real-world assets meet global trading infrastructure
-
Judge allows gun as evidence in Mangione healthcare exec murder trial
-
First attack on Arab nuclear site sends warning to Gulf, US
-
Oil rises, bond yields weigh on stocks
-
Hormuz tanker traffic edges higher after wartime low
-
Andalusia setback highlights weakness of Spain's ruling Socialists
-
India's Adani to pay $275 mn settlement to US over alleged Iran sanctions violations
-
Middle East tourism pain is Europe's gain
-
UK Labour leadership hopeful reopens Brexit debate
-
PSG's Dembele has treatment for leg issue before Champions League final
-
Spurs must play with 'courage' to seal safety: De Zerbi
-
Hantavirus-hit cruise ship ends deadly voyage
-
Champagne start in Reims for 2028 Tour de France
-
Dogs allowed on new Brigitte Bardot beach in glitzy Cannes
-
Oil prices dip on report of US sanctions relief for Iran during talks
-
Croatia names Modric-led World Cup squad
-
Iran World Cup squad lands in south Turkey for training
-
Mushfiqur ton leaves Pakistan needing record run chase to beat Bangladesh
-
Transport protests hit Kenya over rising fuel prices
-
Ex-Google exec takes reins at under-fire BBC
-
France unveils architects to transform Louvre
-
'Mesmeric' movie on secret lives of Nigeria's rich wows Cannes
-
Ex-Google man takes reins at under-fire BBC
-
Swatch blames shopping centres for 'problems' with star product launch
-
Carvajal to leave Real Madrid at end of season
-
Stocks drop, oil climbs after fresh Trump warning to Iran
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
J.AbuHassan--SF-PST